Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.65 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.61 |
| ▸ | PGK1 | P00558 | 2/20 | 0.60 |
| ▸ | PGK2 | P07205 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383886 | 1.00 | ADORA2A (0.65) | ADORA2AADORA2BSLC29A1ADORA3ADORA1 | |
| SCHEMBL3949633 | 0.91 | PGK1 (0.73) | ADORA2AADORA2BSLC29A1ADORA3PGK1 | |
| SCHEMBL5392874 | 0.91 | PGK1 (0.73) | ADORA2AADORA2BSLC29A1ADORA3PGK1 | |
| SCHEMBL4806847 | 0.89 | PGK1 (0.71) | ADORA2AADORA2BSLC29A1ADORA3ADORA1 | |
| SCHEMBL5381003 | 0.89 | ADORA3 (0.75) | ADORA2AADORA2BSLC29A1ADORA3ADORA1 | |
| SCHEMBL3955616 | 0.89 | ADORA3 (0.75) | ADORA2AADORA2BSLC29A1ADORA3ADORA1 | |
| SCHEMBL5381010 | 0.84 | ADORA3 (0.79) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL638136 | 0.84 | SLC29A1 (0.82) | ADORA2ASLC29A1ADORA3ADORA1TP53 | |
| SCHEMBL17825905 | 0.84 | SLC29A1 (0.82) | ADORA2ASLC29A1ADORA3ADORA1TP53 | |
| SCHEMBL20626338 | 0.84 | SLC29A1 (0.82) | ADORA2ASLC29A1ADORA3ADORA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156544-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ELZEIN ELFATIH | 2009-06-18 | — | — | US | disclosed |
| US-7514417-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7381714-B2 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1883646-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1881991-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060281705-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-20060276428-A1 | A1 adenosine receptor agonists | CV THERAPEUTICS, INC. | 2006-12-07 | — | — | US | disclosed |
| WO-2006125190-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006125211-A1 | A1 ADENOSINE RECEPTOR AGONISTS | CV THERAPEUTICS, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156544-A1 | A1 ADENOSINE RECEPTOR AGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 4/4885SLC29A1 124/4885 |
| US-20060281705-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 4/4885SLC29A1 124/4885 |
| US-20060276428-A1 | A1 adenosine receptor agonists | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 4/4885SLC29A1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.